PSORENT Features a Unique and Innovative Formulation Available Without a
Prescription Through Physicians
PRINCETON, N.J., Feb. 4 /PRNewswire/ -- NeoStrata today announced the launch of PSORENT, a clinically proven, steroid-free, topical treatment for psoriasis. PSORENT contains LCD (liquid carbonis distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced formulation and package that promotes high patient compliance. PSORENT is available without a prescription from dermatologists beginning March 2008.
"With the launch of PSORENT, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "PSORENT's effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients."
PSORENT is an aesthetically advanced, fast absorbing topical coal tar solution that provides a new alternative for psoriasis patients and providers. Optimally formulated with a 15 percent concentration of LCD, the therapeutic equivalent of 2.3 percent coal tar, PSORENT is an innovative topical solution to treat the chronic redness and scaling associated with psoriasis. PSORENT is supplied in a convenient dab-on delivery system that speeds LCD absorption and avoids the stains, odor and mess that are typically associated with coal tar treatments. Additionally, the dab-on applicator allows the patient to apply PSORENT directly to the affected areas without touching either the solution or the skin, resulting in a highly effective and easy to use treatment. PSORENT is available only through physicians' offices. One 100mL bottle provides up to a 3-month supply, at a suggested retail price of $45.00, making it a cost effective alternative to prescription medications which may or may not be covered by health insurance.
Psoriasis is an immune-mediated, genetic disease manifesting in the skin and/or the joints. According to the National Institutes of Health, as many as 7.5 million Americans have psoriasis. The National Psoriasis Foundation defines mild psoriasis as affecting less than three percent of the body; three percent to 10 percent is considered moderate; more than 10 percent is considered severe. According to the National Psoriasis Foundation's Benchmark Survey on Psoriasis and Psoriatic Arthritis, the disease is not merely a cosmetic problem. Nearly 60 percent reported their psoriasis to be a large problem in their everyday life. The survey also indicates that psoriasis had a greater impact on quality of life in women and younger patients.
The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.
|SOURCE The NeoStrata Company|
Copyright©2008 PR Newswire.
All rights reserved